Close Menu

NEW YORK (GenomeWeb) – Qiagen said Wednesday that its Therascreen EGFR RGQ PCR kit has been approved by the Japanese Pharmaceuticals and Medical Device Agency as a companion diagnostic with Pfizer's Vizimpro (dacomitinib) for EGFR mutation-positive, inoperable, or recurrent non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.